NCT05661539

Brief Summary

The researchers aim to determine how baseline (preconceptional) and first-trimester uterine artery Doppler measurements affect obstetric complications in women undergoing high-quality blastocyst transfer and to determine the correlation between the two Doppler measurements.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2022

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

December 14, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

December 22, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2024

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 15, 2024

Completed
Last Updated

May 23, 2023

Status Verified

May 1, 2023

Enrollment Period

1.6 years

First QC Date

December 14, 2022

Last Update Submit

May 20, 2023

Conditions

Keywords

Uterine Artery Doppler VelocimetryBaseline Uterine Artery Doppler VelocimetryFirst Trimester Uterine Artery Doppler Velocimetry

Outcome Measures

Primary Outcomes (2)

  • Live Birth Rate

    pregnancy beyond 24 weeks of gestational age.

    9 months

  • Obstetric Complication Rates

    Conditions such as preeclampsia, eclampsia, fetal growth restriction, oligohydramnios, polyhydramnios, preterm birth, gestational diabetes mellitus, antenatal bleeding and etc. that develop during pregnancy

    20 weeks after embryo transfer

Study Arms (3)

non-pregnant

negative b-hCG results 9 days after embryo transfer.

Device: Transvaginal Ultrasonography

pregnant with obstetric complications

Patients with a positive pregnancy result who develop obstetric complications such as preeclampsia, eclampsia, fetal growth restriction, oligohydramnios, polyhydramnios, preterm birth, gestational diabetes mellitus, antenatal bleeding and etc. after the 20th gestational weeks.

Device: Transvaginal Ultrasonography

pregnant without obstetric complications

Patients who have positive pregnancy results and do not have any obstetric complications such as preeclampsia, eclampsia, fetal growth restriction, oligohydramnios, polyhydramnios, preterm birth, gestational diabetes mellitus, antenatal bleeding and etc. during pregnancy.

Device: Transvaginal Ultrasonography

Interventions

The amount of resistance and blood flow in the main arteries that provide uterine perfusion will be determined by uterine artery Doppler velocimetry performed on the patients.

non-pregnantpregnant with obstetric complicationspregnant without obstetric complications

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

All patients who have artificial endometrial preparation with high-quality blastocysts between May 2022 and December 2022 will be included.

You may qualify if:

  • Exogenous hormone preparation of the endometrial lining
  • High embryo quality ((≥2BB) according to Alpha criteria
  • Embryo transfer at the blastocyst stage

You may not qualify if:

  • Patients whose treatments were canceled for any reason before the embryo transfer procedure
  • Patients who underwent embryo transfer in the cleavage stage
  • Presence of low-quality (\<2BB) blastocysts
  • \>15% loss of viability of the embryo during embryo thawing,
  • Patients with congenital uterine malformations,
  • Patients in whom Doppler velocimetry cannot be performed optimally

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Akdeniz University

Antalya, 07700, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Infertility, Female

Condition Hierarchy (Ancestors)

Genital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesInfertility

Study Officials

  • ŞAFAK OLGAN, MD

    Akdeniz University

    PRINCIPAL INVESTIGATOR
  • ARİF ÖZSİPAHİ, MD

    Akdeniz University

    STUDY CHAIR

Central Study Contacts

ŞAFAK OLGAN, MD

CONTACT

ARİF C ÖZSİPAHİ, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

December 14, 2022

First Posted

December 22, 2022

Study Start

June 1, 2022

Primary Completion

January 1, 2024

Study Completion

April 15, 2024

Last Updated

May 23, 2023

Record last verified: 2023-05

Locations